Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir and Florbetapir PET Imaging in CTE Risk
NCT02079766Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Jun 2014
- Primary completion
- Oct 2015
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Flortaucipir Visual Read as CTE Biomarker and Relationship Between Clinical Presentation and Tau Deposition. Started Jun 2014; status: completed.
Beyond the preview
Go deeper on NCT02079766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079766.